Co-Authors
This is a "connection" page, showing publications co-authored by HAGOP M KANTARJIAN and ROBERT ORLOWSKI.
Connection Strength
0.321
-
Clonal evolution of hematopoietic stem cells after cancer chemotherapy. bioRxiv. 2024 May 24.
Score: 0.060
-
The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types. Cancer. 2020 07 15; 126(14):3192-3201.
Score: 0.046
-
Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma. Cancer. 2018 06 15; 124(12):2561-2569.
Score: 0.040
-
Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy. Leukemia. 2018 02; 32(2):353-363.
Score: 0.038
-
ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma. Cancer Cell. 2017 07 10; 32(1):88-100.e6.
Score: 0.037
-
Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers. Clin Cancer Res. 2017 06 01; 23(11):2891-2904.
Score: 0.036
-
ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. Sci Signal. 2016 Feb 16; 9(415):ra17.
Score: 0.034
-
Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Feb; 15(2):110-4.
Score: 0.031